Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Marker Therapeutics (MRKR) over the last 9 years, with Q3 2025 value amounting to $16.8 million.

  • Marker Therapeutics' Shares Outstanding (Diluted Average) rose 8779.96% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.8 million, marking a year-over-year increase of 8779.96%. This contributed to the annual value of $9.0 million for FY2024, which is 193.91% up from last year.
  • Per Marker Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $16.8 million for Q3 2025, which was up 8779.96% from $14.0 million recorded in Q2 2025.
  • Marker Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $83.1 million during Q3 2021, with a 5-year trough of $7.7 million in Q4 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $19.8 million, with a median of $8.9 million in 2024.
  • Per our database at Business Quant, Marker Therapeutics' Shares Outstanding (Diluted Average) plummeted by 8993.73% in 2022 and then soared by 8779.96% in 2025.
  • Marker Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $7.7 million in 2021, then rose by 9.16% to $8.4 million in 2022, then increased by 5.49% to $8.8 million in 2023, then rose by 1.94% to $9.0 million in 2024, then surged by 86.61% to $16.8 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $16.8 million for Q3 2025, versus $14.0 million for Q2 2025 and $11.1 million for Q1 2025.